Mylan apparently doesn’t know when to quit. The Epipen isn’t “preventative medicine” and therefore doesn’t seem to fit these rules. But that won’t stop the lobbyists from trying to get on the list.
(From The Washington Examiner)
“This is a blatant attempt to twist the notion of prevention to get first-dollar coverage, specifically to deflect legitimate concerns about the dramatic and as of now indefensible increase in the cost of the device,” according to an article written by several doctors with the American Board of Pediatrics published Tuesday in the journal Annals of Internal Medicine.
The authors say that recommending the EpiPen for the coverage could ensure higher co-pays and deductibles from insurers for non-preventive services as insurers look to pass on the costs to consumers in other ways. That is especially important as the authors say that the EpiPen is not a preventive medicine, but instead is used to treat a life-threatening event of anaphylactic shock.